91插插视频,91熟女露脸视频,精品国产综合一区,跪舔内射人妻

CN
Latest stock price:
XLifes once again named “top 50 biotechnology enterprises” of GAB
Time:2019-10-17  

Source: Guangdong Medical Valley

On October 16, the second award ceremony for the top 50 biotechnology innovation enterprises in Guangdong-Hong Kong-Macao Greater Bay Area "(GBA")was held in Guangzhou. Xiangxue Life Sciences, Ltd (herein after referred to as XLifes"), a subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd., has won the award for the second consecutive year. 

The purpose of the award is to promote integration of production, learning and research, discover biotechnology unicorns, and identify leaders of the biotechnology industry in the GBA. The top 50 enterprises include enterprises in medical devices, biopharmaceuticals (including biotherapy, cell therapy, gene therapy) and medical services (including mobile medicine, pension service, physical examination center, etc.).

The panel for the award composed of experts from government agencies, research institutions, investment institutions, medical institutions, etc. After comprehensive evaluation of the technological innovation and future development prospect of the runner up enterprises through field visits and face-to-face discussions with the enterprises. 

 
【About Xiangxue Life Sciences, Ltd】

Xiangxue Life Sciences, Ltd (“XLifes“) is a biomedical company focusing on TCR-based therapies for cancer. Our main technological platform is TCR Affinity Enhanced Specific T-cells (TAEST).

The product is a kind of affinity optimized TCR engineered T cells (3rd generation TCR-T). With its enhanced TCR affinity, TAEST targets specifically the intracellular and extracellular tumor antigens and exhibits encouraging clinical efficacy and safety profile. In addition, it has longer in vivo persistency and good therapeutic effects in solid tumors.

We have obtained the investigational new drug (IND) approval for our product TAEST16001 from the NMPA in March 2019, and now we are in the progress of recruiting patients. This is the first TCR-T cell therapy IND approved by the NMPA in China.
XPH Group
XLifeSc
Pharmaceutical
TCM Resources
精品欧美乱码久久久| 黄色一级a一片| CAOPORN.COM 超碰| 中国淫片a| 女生自慰网站| 日韩欧美片在线视频| 色A综合网站| 色婷婷久久在线| 亚洲无限观看国产| 插入小穴视频色| 高清中文字幕一本吃瓜| 欧美一级黄片儿| 亚洲三区久久久| 日本成人影院东京热| 日韩电影人人操| 日本综合欧美天堂| 免费精品综合久久| 欧美熟女肛门| 亚洲精品蜜| 日本乱伦大香蕉视频| 亚洲日韩舔色图av| 欠久精品无码一区二区三区| 人妻少久久久久| 91成人在线欧| 久久综久久综合色| 色偷偷一区二区| 欧美女优一区二区| 欧美精品6页| 国产1级黄片儿| 日韩999999精品视频在线播放| 天堂A√久久| 曰韩无码Av白云影院Av| 日本一区二区不卡我不卡日本| 99久久国产综合精品123| 中文字幕乱码日本亚洲一区二区| 大美女操大逼逼| 欧美国产无码日韩| 后入少妇P| 国语 熟女 对白 精品| 大鸡巴操大骚逼AV网| 人人人操超碰密桃|